Leerink raised the firm’s price target on Lenz Therapeutics (LENZ) to $36 from $32 and keeps an Outperform rating on the shares after the company reported Q3 numbers and provided incremental business updates. The firm says that everything it heard on the call confirms its positive view on the name, and continues to believe that the presbyopia market is a significant opportunity and that the positive results of the Phase 3 trial in China unlock another significant market opportunity ex-U.S. Leerink looks forward to the approval of LNZ100 in August 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LENZ:
- Lenz Therapeutics reports Q3 EPS (38c), consensus (46c)
- Lenz Therapeutics, Corxel Pharmaceuticals report topline data from JX07001 trial
- One new option listing and ten option delistings on October 21st
- Lenz Therapeutics announces FDA acceptance of NDA for LNZ100
- William Blair biotech analysts hold an analyst/industry conference call
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
